Lundbeck announces promising results from Ebixa studies  

The Danish pharmaceutical company and Forest Laboratories Inc. have announced preliminary and positive results for Alzheimer drug

Danish pharmaceutical company Lundbeck and its collaboration partner Forest Laboratories have announced their preliminary results of two phase III studies on the drug Ebixa (memantine) for the treatment of mild to moderate Alzheimer's disease. The results show that patients receiving memantine performed significantly better than patients receiving placebo.


Claus Braestrup, CEO of Lundbeck, says about one of the studies, that the results are clearly positive and show significant efficacy and tolerability of memantine in mild to moderate Alzheimer patients. Forest Laboratories expects to file for a US registration of memantine in mid-2004, while Lundbeck together with its licensor Merz Pharmaceuticals will initiate registrations in a number of countries.


H. Lundbeck A/S markets drugs for the treatment of psychiatric and neurological disorders, and is internationally known for its antidepressant drugs Cipramil and Cipralex (Celexa and Lexapro in US). In 2002, the company's turnover was DKK 9.5 billion (USD 1.6 billion). The news is reported by national newspaper Jyllands-Posten and on Lundbeck's website.


Link > Lundbeck

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×